Onconova Therapeutics Inc.

237 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data AnalysisTopline INSPIRE Results are Expected by the End of the Third Quarter of 2020

  7/29/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the required number of survival events for the pivotal Phase 3 INSPIRE has been reached.

• Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease

  7/27/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has submitted an application with the National Institute of Allergy and Infectious Disease (NIA

• Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy

  7/23/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the publication (Molecular Cell 79, 180-190, 2020) of in vitro data further supporting rigosertib’s role in modulating RAS cellular signaling. “We believe this data sheds light on the capacity of Onconova’s targeted an

• Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS

  7/7/2020

  RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies

• Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar

  6/23/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced its participation in the Noble Capital Markets c-suite webinar series. The webinar was led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D., with participation by Steven M. Fruchtman, M.D., President and

• Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

  6/22/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS) today announced an investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) lung adenocarcinoma has begun enrolling patients. “Over half of non-small cell lung cancers are cl

• Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)

  6/12/2020

  RAS Pathway Mutations Were Observed More Commonly in Patients That Progressed on HMA Therapy vs Patients That Failed HMA Therapy Completely

• Onconova Therapeutics Announces Presentation at BIO Digital 2020

  6/8/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Avi Oler, Senior Vice President, Corporate Development, will present at BIO Digital 2020, being held virtually June 8 - 12, 2020. Mr. Oler will provide an overview of the Company’s corporate development objectives

• Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial ResultsConference Call and Webcast Scheduled Today, May 14 at 4:30 p.m. ET

  5/14/2020

  Onconova Therapeutics, Inc., a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes, reported financial results for the quarter ended March 31, 2020, and provided a business update.

• Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders

  5/11/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that, as disclosed in the Company’s Definitive Proxy Statement for the Company’s 2020 Annual Meeting of Stockholders, due to the public health impact of the COVID-19 pandemic, the Company’s Annual Meeting of Stockholders

• Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, May 14

  5/7/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company will release its first quarter financial results on Thursday, May 14, 2020, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss thes

• Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry Veteran

  4/27/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the nomination of biotech industry veteran Terri Shoemaker to the Company’s Board of Directors. Ms. Shoemaker brings more than 30 years of extensive commercial and leadership experience to Onconova. Ms. Shoemaker will j

• Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results

  3/24/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results for the year ended December 31, 2019 and provided a corporate update.

• Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial ResultsCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Tuesday, March 24, 2020

  3/18/2020

  Onconova Therapeutics, Inc. today announced that the Company will release its year-end 2019 financial results on Tuesday, March 24, 2020, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these resu

• Onconova Therapeutics Announces Participation in Two Upcoming International Conferences

  2/18/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company will be participating in two upcoming international conferences:

• Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FL

  2/10/2020

  NEWTOWN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, February 17-18, 2020, being held in Hollywood, FL.  Dr.

• Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City

  2/4/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 10-11, 2020.

• Onconova Therapeutics Regains Rigosertib Rights in Greater China

  1/23/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has regained the rights to rigosertib in Greater China. 

• Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market

  1/3/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the closing of its previously announced registered direct offering of 27,662,518 shares of its common stock at a purchase price of $0.3615 per share,

• Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market

  12/31/2019

  H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.